VANCOUVER, BRITISH COLUMBIA -- (Marketwire - Sept. 20, 2010) -
Berkley Resources Inc. (CNSX:BKS) (PINK SHEETS:BRKDF) (FRANKFURT:W8O) reports it has purchased 200,000 common shares of Vancouver-based TrichoScience Innovations Inc. at a price of CDN$1.00 per share. TrichoScience, a privately-held Life Sciences company, has developed and patented a new hair cell replication technology called Replicel™ that has the potential to become an effective, non-surgical treatment for pattern baldness and other forms of hair loss in both men and women. Berkley's share purchase represents 2.13% of TrichoScience's issued and outstanding share capital.
The Replicel™ procedure is based on autologous cell implantation technology that replicates a patient's hair cells from their own healthy hair follicles. When reintroduced into areas of hair loss, the replicated cells initiate natural hair regeneration. Replicel™ will undergo Stage 1 Human Clinical Trials beginning in late 2010. For more information about TrichoScience and Replicel™ visit www.trichoscience.com.
ABOUT BERKLEY RESOURCES INC.
Berkley is a growth-oriented and diversified venture company pursuing opportunities in both Canada and the United States. The company's shares trade on the Canadian National Stock Exchange (CNSX) under the symbol BKS and in the U.S. under the symbol BRKDF.
For more information visit: www.berkleyresources.com.
ON BEHALF OF THE BOARD
Matt Wayrynen
President and Chief Executive Officer
Contact Information
Gross Capital, Inc.
Barry Gross
Investor Contact
(361) 949-4999
berkley@grosscapital.com
or
Berkley Resources Inc.
Terry Dove
Company Contact
(604) 248-8730
(604) 682-3600 (FAX)
info@berkleyresources.com
www.berkleyresources.com
